CPHI PE Ratio & Valuation,Is CPHI Overvalued

CPHI Relative Valuation

CPHI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CPHI is overvalued; if below, it's undervalued.

Historical Valuation

China Pharma Holdings Inc (CPHI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of China Pharma Holdings Inc (CPHI) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：1.53

Fair

0.00

EV/EBITDA

China Pharma Holdings Inc. (CPHI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.14

EV/EBIT

China Pharma Holdings Inc. (CPHI) has a current EV/EBIT of 0.14. The 5-year average EV/EBIT is 0.22. The thresholds are as follows: Strongly Undervalued below -0.10, Undervalued between -0.10 and 0.06, Fairly Valued between 0.39 and 0.06, Overvalued between 0.39 and 0.55, and Strongly Overvalued above 0.55. The current Forward EV/EBIT of 0.14 falls within the Historic Trend Line -Fairly Valued range.

0.00

China Pharma Holdings Inc. (CPHI) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

China Pharma Holdings Inc. (CPHI) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

China Pharma Holdings Inc. (CPHI) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

China Pharma Holdings Inc (CPHI) has a current Price-to-Book (P/B) ratio of 0.92. Compared to its 3-year average P/B ratio of 0.75 , the current P/B ratio is approximately 23.35% higher. Relative to its 5-year average P/B ratio of 1.89, the current P/B ratio is about -51.04% higher. China Pharma Holdings Inc (CPHI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -12.28%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -10.65% , the current FCF yield is about -100.00% lower.

0.92

P/B

Median3y

0.75

Median5y

1.89

2.00

FCF Yield

Median3y

-12.28

Median5y

-10.65

Competitors Valuation Multiple

The average P/S ratio for CPHI's competitors is 0.90, providing a benchmark for relative valuation. China Pharma Holdings Inc Corp (CPHI) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -31.26%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CPHI decreased by 34.19% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.36 to -1.52.

The secondary factor is the Margin Expansion, contributed -15.22%to the performance.

Overall, the performance of CPHI in the past 1 year is driven by P/E Change. Which is more unsustainable.

-31.26%

1.10M → 756.22K

Revenue Growth

-15.22%

-101.61 → -86.15

Margin Expansion

12.29%

-1.36 → -1.52

P/E Change

-34.19%

2.33 → 1.53

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is China Pharma Holdings Inc (CPHI) currently overvalued or undervalued?

What is China Pharma Holdings Inc (CPHI) fair value?

CPHI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of China Pharma Holdings Inc (CPHI) is between to according to relative valuation methord.

How does CPHI's valuation metrics compare to the industry average?

The average P/S ratio for CPHI's competitors is 0.90, providing a benchmark for relative valuation. China Pharma Holdings Inc Corp (CPHI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -31.26%, this premium appears unsustainable.

What is the current P/B ratio for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?

As of Dec 16 2025, China Pharma Holdings Inc (CPHI) has a P/B ratio of 0.92. This indicates that the market values CPHI at 0.92 times its book value.

What is the current FCF Yield for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?

As of Dec 16 2025, China Pharma Holdings Inc (CPHI) has a FCF Yield of 0.00%. This means that for every dollar of China Pharma Holdings Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?

As of Dec 16 2025, China Pharma Holdings Inc (CPHI) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of China Pharma Holdings Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?

As of Dec 16 2025, China Pharma Holdings Inc (CPHI) has a Forward P/S ratio of 0.00. This means the market is valuing CPHI at $0.00 for every dollar of expected revenue over the next 12 months.

CPHI Valuation

CPHI Valuation

CPHI Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is China Pharma Holdings Inc (CPHI) currently overvalued or undervalued?

What is China Pharma Holdings Inc (CPHI) fair value?

How does CPHI's valuation metrics compare to the industry average?

What is the current P/B ratio for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?

What is the current FCF Yield for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?

What is the current Forward P/E ratio for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?

What is the current Forward P/S ratio for China Pharma Holdings Inc (CPHI) as of Dec 16 2025?